Corporate
2018.02.22
USPTO granted LT3001 patent
US Patent Granted for Lumosa's New Drug to Treat Acute Ischemic Stroke
(Taipei, Taiwan. February 22, 2018) Lumosa Therapeutics (6535.TWO) is pleased to announce that USPTO has issued the US patent (No. US9890193) for the company's new drug candidate, LT3001, which is under development for the treatment of acute ischemic stroke. This is the second patent approval of LT3001 in a major market after the State Intellectual Property Office of China granted LT3001 patent in 2017. Intellectual property of LT3001 is now protected in the two largest pharmaceutical markets in the world, which enhanced the market value of LT3001.
The "substance patent" granted by the USPTO for LT3001 will remain valid until June of 2034. It is considered the most enforceable type of patent for pharmaceutical products, which covers claims for the chemical compound, derivatives, and its pharmaceutical composition thereof. It also covers therapeutic use of the composition in thrombolytic, anti-thrombus, stoke and cerebral infarction conditions. Lumosa had filed patent applications for LT3001 in 16 other jurisdictions worldwide, and additional patent issuance is expected in the near future, which will secure the exclusive right to sell LT3001 worldwide.
World Health Organization estimated 15 million people worldwide suffer stroke each year. Of those, 5 million will die and another 5 million will be permanently disabled1. There are two types of cerebral stroke: Ischemic stroke which accounts for approximately 80 percent of all stroke, and hemorrhagic stroke which accounts for the remaining 20 percent.
LT3001 is a novel small molecule indicated for the treatment of acute ischemic stroke. Its thrombolytic and neuro-protective activities were demonstrated in multiple animal models. If successfully developed, LT3001 may provide a revolutionary therapy to acute ischemic stroke and significantly improve quality of life of stroke patients; further reduce healthcare burden and social costs .
The market size is estimated to be more than US$15 billion for LT3001 if it can overcome the limitations of current therapy and achieve the treatment target of 50% cerebral stroke patients.
________________________________________
1 http://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html
(Taipei, Taiwan. February 22, 2018) Lumosa Therapeutics (6535.TWO) is pleased to announce that USPTO has issued the US patent (No. US9890193) for the company's new drug candidate, LT3001, which is under development for the treatment of acute ischemic stroke. This is the second patent approval of LT3001 in a major market after the State Intellectual Property Office of China granted LT3001 patent in 2017. Intellectual property of LT3001 is now protected in the two largest pharmaceutical markets in the world, which enhanced the market value of LT3001.
The "substance patent" granted by the USPTO for LT3001 will remain valid until June of 2034. It is considered the most enforceable type of patent for pharmaceutical products, which covers claims for the chemical compound, derivatives, and its pharmaceutical composition thereof. It also covers therapeutic use of the composition in thrombolytic, anti-thrombus, stoke and cerebral infarction conditions. Lumosa had filed patent applications for LT3001 in 16 other jurisdictions worldwide, and additional patent issuance is expected in the near future, which will secure the exclusive right to sell LT3001 worldwide.
World Health Organization estimated 15 million people worldwide suffer stroke each year. Of those, 5 million will die and another 5 million will be permanently disabled1. There are two types of cerebral stroke: Ischemic stroke which accounts for approximately 80 percent of all stroke, and hemorrhagic stroke which accounts for the remaining 20 percent.
LT3001 is a novel small molecule indicated for the treatment of acute ischemic stroke. Its thrombolytic and neuro-protective activities were demonstrated in multiple animal models. If successfully developed, LT3001 may provide a revolutionary therapy to acute ischemic stroke and significantly improve quality of life of stroke patients; further reduce healthcare burden and social costs .
The market size is estimated to be more than US$15 billion for LT3001 if it can overcome the limitations of current therapy and achieve the treatment target of 50% cerebral stroke patients.
________________________________________
1 http://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html
